DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients

Medical Hypotheses

Volumn 63, Issue 4, 2004, Pages 684-687

  Altundag, Ozden ^a   Altundag, Kadri ^a,c   Gunduz, Mehmet ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b OKAYAMA UNIVERSITY   (Japan)

^c USA ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DINUCLEOTIDE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROCAINAMIDE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CPG ISLAND; DEATH; DEMETHYLATION; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ESTROGEN ACTIVITY; FOLLOW UP; GENE SILENCING; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HORMONAL THERAPY; HUMAN; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RELAPSE; REPRESSOR GENE; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 8444240727     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.03.017     Document Type: Article

References (26)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 2:1896;104-107
2. Iwase H., Zhang Z., Omoto Y., et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother. Pharmacol. 52(Suppl 1):2003;S34-S38
3. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12:2001;1527-1532
4. Clarke R., Liu M.C., Bouker K.B. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 22:2003;7316-7339
5. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51:1998;227-238
6. Osborne C.K., Zhao H., Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol. 18:2000;3172-3186
7. Webb P., Lopez G.N., Uht R.M., et al. Tamoxifen activation of theestrogen receptor/AP-1 pathway: potential origin for the cell-specificestrogen-like effects of antiestrogens. Mol. Endocrinol. 9:1995;443-456
8. Liu M.M., Albanese C., Anderson C.M., et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem. 277:2002;24353-24360
9. Speirs V., Carder P.J., Lane S., et al. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol. 5:2004;174-181
10. Strom A., Hartman J., Foster J.S., et al. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA. 101:2004;1566-1571
11. Leygue E., Dotzlaw H., Watson P.H., Murphy L.C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 58:1998;3197-3201
12. Omoto Y., Inoue S., Ogawa S., et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 163:2001;207-212
13. Ogawa S., Inoue S., Watanabe T., et al. Molecular cloning and characterization of human estrogen receptor beta cx: a potential inhibitor of estrogen action in human. Nucleic Acids Res. 26:1998;3505-3512
14. Karpf A.R., Jones D.A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 21:2002;5496-5503
15. Bender C.M., Zingg J.M., Jones P.A. DNA methylation as a target for drug design. Pharmacol. Res. 15:1998;175-187
16. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 20:1980;85-93
17. Scheinbart L.S., Johnson M.A., Gross L.A., Edelstein S.R., Richardson B.C. Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 18:1991;530-534
18. Lin X., Asgari K., Putzi M.J., et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61:2001;8611-8616
19. Villar-Garea A., Fraga M.F., Espada J., Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 63:2003;4984-4989
20. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 9:2003;1596-1603
21. Horvath L.G., Henshall S.M., Lee C.S., et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61:2001;5331-5335
22. Leav I., Lau K.M., Adams J.Y., et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159:2001;79-92
23. Witte D., Chirala M., Younes A., Li Y., Younes M. Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum. Pathol. 32:2001;940-944
24. Li L.-C., Yeh C.-C., Nojima D., Dahiya R. Cloning and characterization of human estrogen receptor β promoter. Biochem. Biophys. Res. Commun. 275:2000;682-689
25. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72:1998;141-196
26. Skliris G.P., Munot K., Bell S.M., et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J. Pathol. 201:2003;213-220